MedTrace Logo

Study SC-101 in Subjects With Advanced Malignancies

NCT06220838 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-29

No results posted yet for this study

Summary

This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SC-101

All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.

Sponsors & Collaborators

  • Tianjin ConjuStar Biologics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2026-03-31
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220838 on ClinicalTrials.gov